PMA device
Belotero Balance (+) Lidocaine Dermal Filler
Merz North America, Inc. · Implant, Dermal, For Aesthetic Use (LMH, Class III) · First FDA decision Aug 29, 2019, newest Oct 10, 2025Aesthetic skin, fat and body contouring
Last checked: Nov 20, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
4
PMA pathway
Device trials
95
Naming "Belotero Balance Lidocaine"
MAUDE reports
39
Brand "Belotero Balance Lidocaine", since 2015
PubMed studies
5
Mentioning "Belotero Balance Lidocaine"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing Belotero Balance (+) Lidocaine Dermal Filler
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology, with pictures of the device
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 4 of 4 decisions filed under this name.
- Belotero Balance (+) Lidocaine Dermal FillerPMA supplement
P090016-S066 · Decided Oct 10, 2025 · 87 days after receipt · Normal 180 Day Track
Device type: Implant, dermal, for aesthetic use (LMH) · General & Plastic Surgery
3 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
No Medicare coverage document has a title matching this device or device type. Many devices are paid under existing codes without one.
Clinical trials
Device studies on ClinicalTrials.gov that name "Belotero Balance Lidocaine", any status and sponsor, newest update first.
- Genicular Nerve Radiofrequency Ablation Versus Hyaluronic Acid Injection for Knee Osteoarthritis PainNot yet recruiting
Hospital Universitari Joan XXIII de Tarragona.Academic, hospital or other
NCT07901374 · 70 participants (planned) · Start Nov 2026 · Primary completion May 2028
Device: Intra-articular Hyaluronic Acid · For: Knee Osteoarthritis; Chronic Knee Pain
Sites: Tarragona, Spain
94 more trials with a free account
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "Belotero Balance Lidocaine", and for the whole product code for context.
This brand
39 reports: 0 malfunction, 39 injury, 0 death
Whole product code LMH
16,542 reports: 1,388 malfunction, 15,105 injury, 12 death
Newest reports for this brand
3013840437-2026-00141 · Received Oct 8, 2026 · Event dated Oct 1, 2026
Device type: Implant, Dermal, For Aesthetic Use (LMH)
Device problem as coded: Off-Label Use; Improper or Incorrect Procedure or Method; Adverse Event Without Identified Device or Use Problem
Patient problem as coded: Obstruction/Occlusion; No Clinical Signs, Symptoms or Conditions
4 more reports with a free account
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "Belotero Balance Lidocaine"[tiab]. The summary above synthesizes these.
- Standardized in vitro analysis of the degradability of hyaluronic acid fillers by hyaluronidase.
Buhren BA, Schrumpf H, Bölke E, et al. · Eur J Med Res · 2018
- Hyaluron Filler Containing Lidocaine on a CPM Basis for Lip Augmentation: Reports from Practical Experience.
Fischer TC, Sattler G, Gauglitz GG · Facial Plast Surg · 2016
- The Assessment, Strategy, and Treatment Protocol: Nasolabial Fold Assessment, Strategy, and Treatment With Hyaluronic Acid Fillers in Chinese Patients.
Li Q, Cui H, Tseng FW, et al. · Plast Reconstr Surg Glob Open · 2025
- A Multicenter Noninferiority Study Comparing Safety and Effectiveness of Hyaluronic Acid Fillers for Correction of Nasolabial Folds in Chinese Subjects.
Li W, Li B, Hofmann M, et al. · Plast Reconstr Surg Glob Open · 2023
- [Lidocaine-containing hyaluronic acid filler on a CPM® basis for lip augmentation : Experience from clinical practice].
Fischer T, Sattler G, Gauglitz G · Hautarzt · 2016Observational Study
Other devices of this type
Also filed under product code LMH.
- RADIESSE® Injectable ImplantMerz North America, Inc. · PMA 2026
- SculptraQ-Med AB · PMA 2024
- Belotero Balance Dermal FillerMerz North America, Inc. · PMA 2026
- Restylane Injectable GelQ-Med AB · PMA 2022
- Restylane® ContourQ-Med AB · PMA 2026
- Juvederm Voluma XCAllergan · PMA 2025
- Juvéderm Voluma XC, Vollure XC, Volbella XC, Volux XC, SkinviveAllergan · PMA 2026
- Restylane® Lyft with LidocaineQ-Med AB · PMA 2025
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.